Analysis
Open Access
Rapid antigen screening of asymptomatic people as a public health tool to combat COVID-19
Kevin L. Schwartz, Allison J. McGeer and Isaac I. Bogoch
CMAJ March 29, 2021 193 (13) E449-E452; DOI: https://doi.org/10.1503/cmaj.210100
Kevin L. Schwartz
Unity Health Toronto (Schwartz); Departments of Medicine (Bogoch), and Laboratory Medicine and Pathobiology (McGeer), and Dalla Lana School of Public Health (Schwartz, McGeer), University of Toronto; Sinai Health System (McGeer); University Health Network (Bogoch), Toronto, Ont.
MD MScAllison J. McGeer
Unity Health Toronto (Schwartz); Departments of Medicine (Bogoch), and Laboratory Medicine and Pathobiology (McGeer), and Dalla Lana School of Public Health (Schwartz, McGeer), University of Toronto; Sinai Health System (McGeer); University Health Network (Bogoch), Toronto, Ont.
MDIsaac I. Bogoch
Unity Health Toronto (Schwartz); Departments of Medicine (Bogoch), and Laboratory Medicine and Pathobiology (McGeer), and Dalla Lana School of Public Health (Schwartz, McGeer), University of Toronto; Sinai Health System (McGeer); University Health Network (Bogoch), Toronto, Ont.
MD MScIn this issue
Article tools
Rapid antigen screening of asymptomatic people as a public health tool to combat COVID-19
Kevin L. Schwartz, Allison J. McGeer, Isaac I. Bogoch
CMAJ Mar 2021, 193 (13) E449-E452; DOI: 10.1503/cmaj.210100
Jump to section
- Article
- Why test people who have no symptoms of COVID-19?
- What rapid antigen tests are available and how should they be evaluated?
- What is the international experience with rapid antigen screening?
- What are the potential harms of rapid antigen screening?
- How can rapid antigen testing be incorporated into Canada’s public health response?
- Footnotes
- References
- Responses
- Metrics
Related Articles
Cited By...
- Avoiding false positive SARS-CoV-2 rapid antigen test results with point-of-care molecular testing on residual test buffer
- Contrer les variants plus virulents du SRAS-CoV-2 demandera une reponse plus ingenieuse a la pandemie
- Countering more virulent SARS-CoV-2 variants will require a smarter pandemic response
- Uptake of SARS-CoV-2 workplace testing programs, March 2020 to March 2021
- Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2